Background: Transcatheter aortic valve replacement (TAVR) programs are growing in the Middle East, but data on treated patients in this region is scarce. We sought in this study to analyze the largest single-center population in Lebanon.
Methods and Results: Baseline clinical, procedural characteristics as well as in-hospital and up to five years follow-up outcomes were collected and analyzed for the 141 patients (80 ± 7 years, 51.8% females) included between 2014 and 2019. All-cause mortality at 30 days found in 5 (3.5%) cases was considered as the primary endpoint while Major Adverse Cardiovascular Events at 30 days as secondary ones: cardiovascular mortality in 3 cases (2.1%), strokes in 1 case (0.7%), percutaneous coronary intervention in 3 cases (2.1%) and myocardial infarction in 3 cases (2.1%). Device success and intended prosthesis performance were achieved in 119 (84.4%) and 121 (85.8%) patients, respectively. Multivariate analysis showed that cardiovascular mortality is strongly associated with end-stage renal failure and peripheral artery disease. The dichotomization of patients into two cohorts A and B corresponding to the first and second 3 years of the TAVR time interval showed slow evolution of TAVR patients to a younger and lower risk population but maintained good results.
Conclusion: TAVR in Lebanon shows satisfactory results and good long-term outcomes. Data from the regional prospective registry is needed to assess the evolution of this therapy in the middle-east region.
Transcatheter Aortic Valve Replacement versus Sutureless Aortic Valve Replacement: A Single Center Retrospective Cohort Study
